SMS Pharmaceuticals shines on getting non-exclusive licence to manufacture, supply of nirmatrelvir
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
SMS Pharmaceuticals is currently trading at Rs. 113.35, up by 5.65 points or 5.25% from its previous closing of Rs. 107.70 on the BSE.
The scrip opened at Rs. 112.15 and has touched a high and low of Rs. 114.50 and Rs. 110.60 respectively. So far 32689 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 199.15 on 05-Aug-2021 and a 52 week low of Rs. 85.00 on 11-Mar-2022.
Last one week high and low of the scrip stood at Rs. 114.50 and Rs. 95.95 respectively. The current market cap of the company is Rs. 911.70 crore.
The promoters holding in the company stood at 67.29%, while Institutions and Non-Institutions held 0.65% and 32.06% respectively.
SMS Pharmaceuticals has received a non-exclusive licence to manufacture and supply of nirmatrelvir through the Medicine Patent Pool to manufacture nirmatrelvir, an oral anti-viral COVID-19 medicine developed by Pfizer to increase broad access of treatment in 95 low and middle income countries.
SMS Pharmaceuticals is a global player in API and intermediates manufacturing having a strong research and manufacturing team supported by state‐of‐the‐art facilities.
